Sign in to view content

Avacincaptad Pegol, A Novel C5 Inhibitor, Reached Statistical Significance in a Pivotal Clinical Trial for Geographic Atrophy Secondary to Dry AMD

Baruch D. Kuppermann, MD, PhD

Video
Published 2020

Related

Early Progression of Atrophy in AMD: Post Hoc Analysis From the GATHER1 Study
David R Lally, MD
Annual Meeting Talks
2022
How Do I Decide to Treat Patients with Geographic Atrophy?
Glenn J. Jaffe, MD
Updates from the Field
2024
Phase 1 Safety Study of Intravitreal (ITV) Anti-High Temperature Requirement A1 (aHtrA1), a Novel Serine Protease Inhibitor, in Patients With GA
William Z. Bridges, MD
Annual Meeting Talks
2020

Category: AMD-Neovascular

See more